ROCKET DOCTOR AI INC.

UNAUDITED CONDENSED INTERIM CONSOLIDATED FINANCIAL STATEMENTS

FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2025, AND 2024

(Expressed in Canadian dollars)

(Expressed in Canadian Dollars)

	September 30, 2025	**December 31, 2024**
	$	$
ASSETS		
Current assets		
Cash	1,889,135	1,231,999
Accounts receivable	77,068	-
Prepaid expenses	177,589	47,193
Total current assets	2,143,792	1,279,192
Note receivable (Note 6)	338,388	-
Fixed assets (Note 7)	12,006	-
Goodwill (Note 5)	17,892,090	-
TOTAL ASSETS	20,386,276	1,279,192
LIABILITIES		
Current liabilities		
Accounts payable and accrued liabilities (Notes 8 & 15)	1,351,608	334,430
Deferred revenue	153,753	-
Loans payable, current portion (Note 9)	198,090	151,995
Contingent consideration, current portion (Note 5)	5,153,827	-
Total current liabilities	6,857,278	486,425
Loans payable, net of current portion (Note 9)	238,140	-
Contingent consideration, net of current portion (Note 5)	3,424,636	-
TOTAL LIABILITIES	10,520,054	486,425
SHAREHOLDERS' EQUITY		
Share capital (Note 11)	37,458,957	25,806,316
Reserve (Note 11)	15,854,200	10,079,845
Accumulated other comprehensive loss	(117,411)	(119,737)
Deficit	(43,329,524)	(34,973,657)
TOTAL SHAREHOLDERS’ EQUITY	9,866,222	792,767
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	20,386,276	1,279,192

Note 1: Nature of business and continuing operations
Note 14: Segmented Information
Note 16: Contingencies
Note 17: Subsequent events

Approved and authorized by the Board on December 1, 2025:

“Essam Hamza”
Essam Hamza, Director

“Kevin Peterson”
Kevin Peterson, Director

The accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements.

ROCKET DOCTOR AI INC.
UNAUDITED CONDENSED INTERIM CONSOLIDATED STATEMENTS OF LOSS AND COMPREHENSIVE LOSS
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2025, AND 2024
(Expressed in Canadian Dollars)

	Three Months Ended September 30, 2025	Three Months Ended September 30, 2024	Nine Months Ended September 30, 2025	Nine Months Ended September 30, 2024
	$	$	$	$
Revenues				
Service revenues	-	10,990	25,369	10,990
Subscription revenues	107,224	-	180,008	-
Patient support fees	421,899	-	836,502	-
Total revenues	529,123	10,990	1,041,879	10,990
Direct costs	63,428	-	119,023	-
Gross margin	465,695	10,990	922,856	10,990
Expenses				
Accretion and financing fees (Note 10)	-	-	-	33,360
Consulting and professional fees (Note 15)	1,166,009	568,104	2,600,344	1,844,190
General and administration	290,641	463,704	866,310	733,776
Advertising and marketing	237,721	-	1,051,356	-
Research	(715)	-	191,216	27,100
Salaries & benefits (Note 15)	513,567	234,221	1,139,779	457,139
Stock-based compensation (Note 11)	1,217,588	(102,957)	2,945,989	730,827
Total expenses	3,424,811	1,163,072	8,794,994	3,826,392
Loss from operations	(2,959,116)	(1,152,082)	(7,872,138)	(3,815,402)
Interest expense	(23,033)	-	(39,243)	-
Foreign exchange gain (loss)	(116,236)	(9,762)	(77,267)	(17,489)
Change in fair value of contingent consideration	(423,975)	-	(367,219)	-
Loss on settlement of payables equity	-	(499,106)	-	(499,106)
Loss on restructuring of convertible debt	-	-	-	(971,435)
Loss for the period	(3,522,360)	(1,660,950)	(8,355,867)	(5,303,432)
Foreign exchange translation	(5,913)	(1,303)	2,326	(8,993)
Comprehensive loss for the period	(3,528,273)	(1,662,253)	(8,353,541)	(5,312,425)
Loss per share – basic and diluted	(0.05)	(0.03)	(0.12)	(0.13)
Weighted average number of outstanding common shares, basic and diluted	77,730,898	48,006,452	68,111,977	41,737,561

The accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements.

ROCKET DOCTOR AI INC.
UNAUDITED CONDENSED INTERIM CONSOLIDATED STATEMENTS OF SHAREHOLDERS' DEFICIENCY
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2025, AND 2024
(Expressed in Canadian Dollars)

	Number of Preferred Shares	Number of Common Shares	Share Capital $	Reserve $	Accumulated Other Comprehensive Loss $	Deficit $	Total $
Balance, December 31, 2023	10,001	37,105,115	19,069,847	7,819,953	(101,169)	(27,526,684)	(738,053)
Shares issued to settle payables	-	1,160,713	1,149,106	-	-	-	1,149,106
Shares issued to settle debts for services	-	1,143,403	1,169,468	263,182	-	-	1,432,662
Shares issued for services	-	39,775	30,627	-	-	-	30,627
Shares issued for exercise of warrants	-	953,690	542,890	-	-	-	542,890
Shares issued for exercise of RSUs	-	700,000	470,000	(470,000)	-	-	-
Shares issued for Unit Placement	-	975,000	263,877	126,123	-	-	390,000
Expiration of warrants	-	-	-	(106,620)	-	106,620	-
Shares issued for automatic conversion of special warrants	-	6,295,500	1,703,832	814,368	-	-	2,518,200
Share issuance costs – cash	-	-	(284,827)	(136,124)	-	-	(420,963)
Share issuance costs – warrants	-	-	(192,808)	192,808	-	-	-
Stock-based compensation	-	-	-	730,827	-	-	730,827
Other comprehensive loss	-	-	-	-	(8,993)	-	(8,993)
Loss for the period	-	-	-	-	-	(5,303,432)	(5,303,432)
Balance, September 30, 2024	10,001	48,373,196	23,922,012	9,234,517	(110,162)	(32,723,496)	322,871
Balance, December 31, 2024	10,001	51,228,628	25,806,316	10,079,845	(119,737)	(34,973,657)	792,767
Shares issued for acquisition of Rocket Doctor Inc.	-	17,000,904	7,480,398	-	-	-	7,480,398
Private placement	-	11,392,000	4,263,971	1,432,029	-	-	5,696,000
Share issuance costs – cash	-	-	(456,685)	(158,687)	-	-	(615,372)
Share issuance costs – warrants	-	-	(242,645)	242,645	-	-	-
Special warrant financing	-	-	-	1,838,700	-	-	1,838,700
Shares issued for the exercise of warrants	-	338,866	152,268	-	-	-	152,268
Shares issued for the exercise of RSUs	-	670,000	443,300	(443,300)	-	-	-
Reclassification on the exercise of warrants	-	-	12,034	(12,034)	-	-	-
Stock based compensation	-	-	-	2,945,990	-	-	2,945,990
Reclassify legal fees to issuance cost	-	-	-	(70,988)	-	-	(70,988)
Other comprehensive loss	-	-	-	-	2,326	-	2,326
Loss for the period	-	-	-	-	-	(8,355,867)	(8,355,867)
Balance, September 30, 2025	10,001	80,630,398	37,458,957	15,854,200	(117,411)	(43,329,524)	9,866,222

The accompanying notes are an integral part of these unaudited condensed interim consolidated financial statements.

ROCKET DOCTOR AI INC.
UNAUDITED CONDENSED INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS
FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2025, AND 2024
(Expressed in Canadian Dollars)

	2025	2024
	$	$
Cash flows used in operating activities		
Loss for the period	(8,355,867)	(5,303,432)
Items not involving cash		
Accretion and financing fees	-	19,080
Depreciation and amortization	621	-
Change in fair value of contingent liabilities	367,219	-
Shares issued for services	-	30,627
Loss on settlement of payables for equity	-	499,105
Loss on settlement of debt	-	971,435
Stock-based compensation	2,945,989	730,827
Changes in non-cash working capital items		
- Receivables	11,072	27,247
- Prepaid expenses	(130,396)	(646,046)
- Accounts payable and accrued liabilities	215,610	190,668
- Deferred revenue	16,778	-
Cash used in operating activities	(4,928,974)	(3,480,489)
Cash flows from investing activities		
Purchase equipment	(3,136)	
Purchase of Rocket Doctor Inc.	(1,386,884)	-
Cash used in investing activities	(1,390,020)	-
Cash flows from financing activities		
Principal payments on loan payable	(26,805)	(15,486)
Proceeds from issuance of loans payable	-	-
Shareholder receivable	-	(10,000)
Exercise of warrants	152,268	542,890
Proceeds from private placement, net of share issue costs	6,848,341	2,487,249
Cash provided by financing activities	6,973,804	3,004,653
Effect of foreign exchange rate on cash	2,326	(8,993)
Net cash inflows (outflows)	657,136	(484,829)
Cash, beginning of period	1,231,999	715,529
Cash, end of period	1,889,135	230,700

1. NATURE OF BUSINESS AND CONTINUING OPERATIONS

Rocket Doctor AI Inc. (formerly Treatment.com AI Inc., the “Company" or “Rocket Doctor AI”) was incorporated on February 2, 2018, pursuant to the provisions of the *Canada Business Corporations Act*. The Company was continued under the *Business Corporations Act* (British Columbia) on June 21, 2023. The Company’s registered head office address is 700-838 W Hastings St., Vancouver, British Columbia, V6C 0A6, Canada.

Rocket Doctor AI, through its wholly owned subsidiaries, Treatment.com Inc. (“Treatment Inc.”), and Rocket Doctor Inc. (“Rocket Doctor”), and its wholly owned subsidiary, Rocket Doctor, Inc. (“Rocket Doctor US”), is in the business of providing personalized health care information that is relevant and trustworthy and providing a proprietary digital health platform to assist physicians to provide comprehensive health care to patients. Rocket Doctor AI products aim to empower patients to make responsible, informed decisions about their health while improving communications, reducing costs and in-clinic wait times for medical and mental health practitioners.

The Company has been relying on equity-based financing to fund its operations. As of September 30, 2025, the Company has yet to generate a positive net income and had an accumulated deficit of $43,329,524. The Company will require additional financing either through equity or debt financing or a combination thereof to meet its administrative costs and to develop its business. There is no assurance that sufficient future funding will be available on a timely basis or on terms acceptable to the Company. These conditions indicate the existence of material uncertainties that cast significant doubt as to the ability of the Company to meet its obligations as they come due, and accordingly, the appropriateness of the use of accounting principles applicable to a going concern is in significant doubt. The unaudited condensed interim consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence. Such adjustments could be material.

2. STATEMENT OF COMPLIANCE

These unaudited condensed interim consolidated financial statements are prepared by the Company in accordance with IFRS Accounting Standards ("IFRS") as issued by the International Accounting Standards Board (“IASB”), in accordance with International Accounting Standards (“IAS”) 34 *Interim Financial Reporting* and should be read in conjunction with the Company’s annual consolidated financial statements for the year ended December 31, 2024.

The policies applied in these unaudited condensed interim consolidated financial statements are based on IFRS issued and outstanding as of December 1, 2025, the date the Board of Directors approved the statements. The same accounting policies and methods of computation are followed in these unaudited condensed interim consolidated financial statements as compared with the most recent annual consolidated financial statements as of and for the year ended December 31, 2024, except as noted below. Any subsequent changes to IFRS that are given effect in the Company’s annual consolidated financial statements for the year ended December 31, 2025, could result in restatement of these unaudited condensed interim consolidated financial statements.

3. MATERIAL ACCOUNTING POLICIES

The accounting policies, critical judgements, and estimates used to prepare these unaudited condensed interim consolidated financial statements are consistent with those applied and disclosed in Note 3 of our consolidated financial statements for the year ended December 31, 2024. Certain comparative balances within profit and loss have been reclassified for the three and nine months ended September 30, 2024, to conform to the current presentation with no impact on overall loss and comprehensive loss.

3. MATERIAL ACCOUNTING POLICIES (continued)

Acquisitions

The Company accounts for acquisitions and investments in businesses as Business Combinations if the target meets the definition of a business and (a) the target is a variable interest entity ("VIE") and the Company is the target's primary beneficiary, and therefore the Company must consolidate its financial statements, or (b) the Company acquires more than 50% of the voting interest of the target and it was not previously consolidated. The Company records Business Combinations using the acquisition method of accounting, which requires all of the assets acquired and liabilities assumed to be recorded at fair value as of the acquisition date. The excess of the purchase price over the estimated fair values of the net tangible and intangible assets acquired is recorded as goodwill. The application of the acquisition method of accounting for Business Combinations requires management to make significant estimates and assumptions in the determination of the fair value of assets acquired and liabilities assumed in order to properly allocate purchase price consideration between assets that are depreciated and amortized from goodwill. The fair value assigned to tangible and intangible assets acquired and liabilities assumed are based on management's estimates and assumptions, as well as other information compiled by management, including valuations that utilize customary valuation procedures and techniques. Significant assumptions and estimates include, but are not limited to, the cash flows that an asset is expected to generate in the future, the appropriate weighted-average cost of capital, and the cost savings expected to be derived from acquiring an asset, if applicable.

If the actual results differ from the estimates and judgments used in these estimates, the amounts recorded in the Company's consolidated financial statements may be exposed to potential impairment of the intangible assets and goodwill.

If the Company's investment involves the acquisition of an asset or group of assets that does not meet the definition of a business, the transaction is accounted for as an asset acquisition. An asset acquisition is recorded at cost, which includes capitalizing transaction costs, and does not result in the recognition of goodwill.

Revenue Recognition

The Company primarily earns revenue through its Software-as-a-Service (SaaS) platform, serving as an intermediary between physicians and patients for virtual care services.

The Company also earns subscription revenues through partnerships with pharmacies.

The Company considers IFRS 5-step revenue recognition framework when assessing appropriate revenue recognition as follows:

- Identify the contract(s) with a customer.
- Identify the performance obligations in the contract.
- Determine the transaction price.
- Allocate the transaction price to the performance obligations in the contract.
- Recognise revenue when (or as) the entity satisfies a performance obligation.

The Company accounts for a contract when it has approval and commitment from both parties, the rights of the parties are identified, payment terms are identified, the contract has commercial substance and collectability of consideration is probable.

The Company evaluates the services promised in each contract at inception to determine whether the Company should account for the contract as having one or more performance obligations. Each of the Company's solutions is capable of being distinct as the customer can benefit from each individual solution on its own or with other resources that are readily available.

3. MATERIAL ACCOUNTING POLICIES (continued)

The Company performs under various types of contracts, which generally include firm-fixed-price and time-and-materials contracts. Under fixed-price contracts, the Company agrees to perform the specified work for a pre-determined price. To the extent the Company's actual costs vary from the estimates upon which the price was negotiated; the Company will generate more or less profit or could incur a loss. Under time-and-materials contracts, the Company agrees to perform the specified work for a pre-determined rate per hour, as well as the reimbursement of other direct billable costs which are presented on a gross basis.

The Company assesses each contract at its inception to determine whether it should be combined with other contracts. When making this determination, the Company considers factors such as whether two or more contracts were negotiated and executed at or near the same time or were negotiated with an overall profit objective. If combined, the Company treats the combined contracts as one single contract for revenue recognition purposes.

The Company recognizes revenue as performance obligations are satisfied and the customer obtains control of the solutions and services. In determining when performance obligations are satisfied, the Company considers factors such as contract terms, payment terms and whether there is an alternative future use of the solution or service. Revenues from patient support services are recognized on a net basis when the virtual care services have been completed. Subscription revenue is recognized ratably over the subscription term as the Company fulfills its performance obligation of hosting a landing page for the subscribing pharmacy. Payments received in advance are recorded as deferred revenue.

Use of Estimates

The preparation of the accompanying consolidated financial statements in conformity with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the accompanying consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

The principal estimates relate to the valuation of, stock options, warrants, allocation of the purchase price of assets relating to business combinations, calculation of contingent consideration for acquisitions, fair value of intangible assets and goodwill impairment.

Goodwill and Goodwill Impairment

Goodwill is recorded as the difference, if any, between the aggregate consideration paid for an acquisition and the fair value of the assets acquired and liabilities assumed. Goodwill is not amortized but instead tested for impairment. The Company tests for impairment on December 31 of each year, or more frequently should an event or a change in circumstances that would indicate the carrying value may be impaired. Such events and circumstances may be a significant change in business climate, economic and industry trends, legal factors, negative operating performance indicators, significant competition or changes in strategy. The Company performs its goodwill impairment test at the reporting unit level. In goodwill impairment tests prior to April 9, 2025, the Company determined it operated under one reporting unit. Given the acquisition of Rocket Doctor on April 9, 2025, the Company determined there were multiple reporting units as of September 30, 2025. Refer to Note 14 for information regarding the Company's reportable segments.

The Company's goodwill impairment analysis is performed, and related impairment charges recorded, after the impairment analysis and recognition of impairment charges for long-lived assets other than goodwill and indefinite-lived intangible assets. In testing goodwill for impairment, the Company first assesses qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. If, after assessing the totality of events or circumstances, the Company determines it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then additional impairment testing is not required. When the Company determines a fair value test is necessary, it estimates the fair value of

3. MATERIAL ACCOUNTING POLICIES (continued)

a reporting unit and compares the result with its carrying amount, including goodwill. If the carrying amount of a reporting unit exceeds its fair value, an impairment is recorded equal to the amount by which the carrying value exceeds the fair value, up to the amount of goodwill associated with the reporting unit.

Determining the fair value of a reporting unit requires the application of judgment and involves the use of significant estimates and assumptions including, projections of future cash flows, revenue growth rates, weighted average cost of capital, selecting appropriate discount rates and other factors which can be affected by changes in business climate, economic conditions, the competitive environment and other factors. The Company bases these fair value estimates on assumptions management believes to be reasonable, but which are unpredictable and inherently uncertain. A change in underlying assumptions would cause a change in the results of the tests and, as such, could cause fair value to be less than the carrying amounts and result in an impairment of goodwill in the future. Additionally, if actual results are not consistent with the estimates and assumptions or if there are significant changes to the Company's planned strategy, it may cause the fair value of the reporting unit to be less than its carrying amount and result in additional impairments of goodwill in the future. The Company corroborates the reasonableness of the total fair value of the reporting units with the Company's market capitalization. The Company's market capitalization is calculated using the relevant shares outstanding and stock price of the Company's publicly traded shares. In the event of a goodwill impairment, the Company would be required to record an impairment, which would impact earnings and reduce the carrying amounts of goodwill on the consolidated balance sheet. No impairment was recorded in the three and nine months ended September 30, 2025

Contingent Consideration

Contingent consideration is recorded within contingent consideration, current portion, and contingent consideration, net of current portion, in the Company's unaudited condensed interim consolidated statements of financial position as of September 30, 2025. Contingent consideration has been recorded at its estimated fair value based on contractual terms and assumptions regarding financial forecasts, discount rates, and volatility of forecasted revenue. The development and determination of the inputs for fair value calculations are the responsibility of the Company's management with, at times, the assistance of a third-party valuation specialist.

4. BASIS OF PRESENTATION

These unaudited condensed interim consolidated financial statements have been prepared on a historical cost basis, except for financial instruments classified as financial instruments at fair value through profit and loss, which are stated at their fair value. In addition, these unaudited condensed interim consolidated financial statements have been prepared using the accrual basis of accounting except for cash flow information. These unaudited condensed interim consolidated financial statements are presented in Canadian dollars unless otherwise noted.

Basis of Consolidation

These unaudited condensed interim consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries Treatment Inc., Rocket Doctor and Rocket Doctor US from the date control was acquired. Control exists when the Company possesses power over an investee, has exposures to variable returns from the investee and has the ability to use its power over the investee to affect its returns. All intercompany balances and transactions have been eliminated.

5. BUSINESS COMBINATION

On February 11, 2025, the Company entered into a definitive share purchase agreement (the "Rocket Doctor SPA"), as amended, with Rocket Doctor and the common shareholders of Rocket Doctor with respect to the proposed acquisition of 100% of the issued and outstanding securities in the capital of Rocket

(Expressed in Canadian Dollars)

5. BUSINESS COMBINATION (continued)

Doctor by the Company. Rocket Doctor is a Canadian federally incorporated company that provides a platform for patients to schedule and attend appointments with medical and mental health providers.

On April 9, 2025 (the "Closing Date"), pursuant to the terms and conditions of the Rocket Doctor SPA, Rocket Doctor AI satisfied amounts owing under Rocket Doctor's existing simple agreement for future equity ("SAFE") and acquired 100% of the total issued and outstanding securities of Rocket Doctor for total consideration equal to (i) 17,000,904 common shares of Rocket Doctor AI, which were paid on closing and (ii) subject to the achievement of certain 12 and 24 month milestones, Rocket Doctor AI shall issue additional common shares of Rocket Doctor AI with a fair market value of up to USD$6,902,560, payable to the former holders of SAFEs and shareholders of Rocket Doctor in accordance with Rocket Doctors' governance and security agreements. The balance of goodwill as of September 30, 2025, reflects the value of the expected synergies of combining the Rocket Doctor AI's technology with Rocket Doctor's platform and network of practitioners.

The acquisition of Rocket Doctor was accounted for as a business combination in accordance with IFRS 3 *Business Combinations*. As the acquirer for accounting purposes, the Company estimated the Purchase Price, assets acquired and liabilities assumed as of the acquisition date, with the excess of the Purchase Price over the fair value of net assets acquired recognized as goodwill. Due to the timing of the closing of this transaction, the purchase accounting is incomplete. An independent valuation expert will assist the Company in determining these fair values.

The primary reason for the acquisition was to use the Company's technology to create efficiencies and aid practitioners on Rocket Doctor's platform. The Company expected that implementing Rocket Doctor AI's planned AI Nurse and leveraging the Global Library of Medicine ("GLM") and conversational voice application would enhance patient triage and onboarding ahead of Rocket Doctor appointments.

Milestone Payments

As noted above, pursuant to the terms of the Rocket Doctor SPA, the former holders of SAFEs and shareholders of Rocket Doctor are eligible to receive milestone payments of up to USD$6,902,560 in the aggregate, consisting of a 12 Month Milestone Payment of up to USD$3,944,320 with respect to the 12-month period ending April 9, 2026 and a 24 Month Milestone Payment of up to USD$2,958,240 with respect to the 24-month period ending April 9, 2027. The actual amount of the 12 Month Milestone Payment and the 24 Month Milestone Payment will be paid in common shares of the Company based on and subject to Rocket Doctor and its subsidiary's achievement of certain annual recurring revenue ("ARR") targets for the applicable periods, as follows:

Annual Recurring Revenue	Value of Common Shares
12 Month Milestone Payment	
$3,000,000	US$1,972,160
$3,250,000	US$2,958,240
$3,500,000	US$3,944,320
24 Month Milestone Payment	
$4,500,000	US$1,479,210
$4,750,000	US$2,218,815
$5,000,000	US$2,958,240

ARR is defined as the total value over the proceeding twelve months of all recognized revenues in accordance with IFRS, plus all otherwise contracted for revenue commitments from customers, stemming from or related to all ongoing revenue sources. Government grants and incentives and one-time payments are excluded from ARR.

(Expressed in Canadian Dollars)

5. BUSINESS COMBINATION (continued)

The Company expects Rocket Doctor to achieve ARR of $3,500,000 in the 12-month period ending April 9, 2026, and $5,000,000 in the 24-month period ending April 9, 2027, and recorded contingent consideration of US$3,944,320 for the 12 Month Milestone Payment and US$2,958,240 for the 24 Month Milestone Payment, less a discount of 12%.

Preliminary Purchase Price Allocation

Accounting guidance provides that an acquirer must recognize adjustments to provisional amounts that are identified during the measurement period, which runs through April 9, 2026, in the measurement period in which the adjustment amounts are determined. The acquirer must record in the financial statements, the effect on earnings of changes in depreciation, amortization or other income effects, if any, as a result of the changes to the provisional amounts, calculated as if the accounting had been completed at the acquisition date. Items that could be subject to adjustment include the recognition of identifiable intangible assets, the value of the milestone payments and the deferred income tax assets or liabilities resulting from the acquisition.

The preliminary acquisition date value of the consideration transferred totaled $16,516,739, which consisted of the following:

		April 9, 2025
Purchase price consideration		
Value of common shares	$	7,480,398
12 Month Milestone Payment		4,929,940
24 Month Milestone Payment		3,281,304
Rocket Doctor debt repaid by Rocket Doctor AI		825,097
Total purchase price consideration	**$**	**16,516,739**

The following is a summary of the preliminary purchase price allocation for Rocket Doctor AI's acquisition of Rocket Doctor:

		April 9, 2025
Assets acquired		
Cash	$	88,496
Accounts receivable		88,140
Prepaid expenses and other current assets		299,286
Fixed assets, net		9,491
Goodwill		17,892,090
Total assets acquired		**18,377,503**
***Liabilities* assumed**		
Accounts payable and accrued liabilities		(801,568)
Deferred revenue		(136,975)
Loans payable to third parties		(311,040)
Loan payable to Rocket Doctor AI		(611,181)
Total liabilities assumed		**(1,860,764)**
Net assets acquired	**$**	**16,516,739**

During the three and nine months ended September 30, 2025, the Company recorded a loss of $367,219, respectively, on the change in the fair value of the contingent consideration.

As a condition of the Rocket Doctor SPA, at closing, the Company paid a total of $825,098 to various lenders to settle loans payable. See Note 8 for discussion of the remaining term loan with BDC.

The Company incurred transaction costs of $12,797 related to the Rocket Doctor SPA, which is recorded in consulting and professional fees on the unaudited condensed interim consolidated statements of loss and comprehensive loss. No share issuance costs were incurred in connection with the Rocket Doctor SPA.

(Expressed in Canadian Dollars)

5. BUSINESS COMBINATION (continued)

From the Closing Date through September 30, 2025, Rocket Doctor recognized revenues of $1,016,510 and incurred a net loss of $2,028,367. The revenue and profit or loss of the combined entity for the current reporting period as though the acquisition date had been as of the beginning of the annual reporting period were $1,577,031 and $7,512,556, respectively.

6. NOTE RECEIVABLE

On February 11, 2025, the Company entered into a Promissory Note ("Rocket Doctor Promissory Note") with Rocket Doctor (see Note 5). Pursuant to the Rocket Doctor Promissory Note, the Company agreed to provide the Rocket Doctor with a loan in the principal amount of $675,000 (the "Rocket Doctor Promissory Note"). The Rocket Doctor Promissory Note matures on the earlier of (a) the 24-month anniversary of the date of termination of the Rocket Doctor SPA (see Note 5) and (b) April 9, 2027. Borrowings under the Rocket Doctor Promissory Note do not bear interest. On April 9, 2025, the Company closed the acquisition of Rocket Doctor in accordance with the terms of the Rocket Doctor SPA. As of April 9, 2025, the Company had funded a total of $611,181 on the Rocket Doctor Promissory Note. As of September 30, 2025, the Rocket Doctor Promissory Note is eliminated in consolidation.

In addition to the Rocket Doctor Promissory Note, from April 9, 2025, to September 30, 2025, the Company paid a total of $850,000 to Rocket Doctor to support operations. These costs are included in general and administrative expenses on the unaudited condensed interim consolidated statements of loss and comprehensive loss.

During the period ended September 30, 2025, the Company had a note receivable from a related private company called Rocket Doctor Practice Group, P.C. in the amount of $338,388, the loan does not bear interest, and there is no fixed repayment term.

7. FIXED ASSETS, NET

As of September 30, 2025, and December 31, 2024, fixed assets consisted of the following:

	As of September 30, 2025		As of December 31, 2024	
	Cost	Accumulated Amortization	Cost	Accumulated Amortization
Computer equipment	$ 69,184	$ 57,178	$ -	$ -
Medical equipment	64,294	64,294	-	-
	133,478	$ 121,472	-	$ -
Less accumulated amortization	121,472		-	
Net book value	$ 12,006		$ -	

During the three and nine months ended September 30, 2025, amortization expense was $617, respectively (three and nine month ended September 30, 2024 - $nil, respectively).

(Expressed in Canadian Dollars)

8. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

As of September 30, 2025, and December 31, 2024, accounts payable and accrued liabilities consisted of the following:

	September 30, 2025	December 31, 2024
General and administrative expenses payable	$ 212,328	$ 50,690
Research and development expenses payable	137,720	95,012
Consulting and professional fees payable	338,255	118,595
Advertising and marketing expenses payable	100,626	37,835
Salaries and benefits payable	125,472	18,837
Sales tax payable	98,879	-
Credit card balances	236,585	-
Due to Doctors	101,737	-
Other	-	13,461
Total accounts payable and accrued liabilities	**$ 1,351,608**	**$ 334,430**

9. LOANS PAYABLE AND LONG-TERM DEBT

As of December 31, 2024, the Company held shareholders' loan in the amount of $151,995. The loans were non-interest bearing, unsecured and payable on demand.

On April 9, 2025, as part of the Company's acquisition of Rocket Doctor, the Company assumed a term loan from the Business Development Bank of Canada ("BDC") in the amount of $311,040 that is interest bearing, with an interest payable on the unpaid principal at a BDC's floating rate (7.05%) plus 4% per annum, maturing on July 31, 2030. The loan is secured by general and continuing security interest in all of the Rocket Doctor's present and after acquired personal property and a personal guarantee by one of the former shareholders. As of September 30, 2025, the total balance of the loan was $286,740, with $48,600 allocated to loans payable, current portion and $238,140 allocated to loans payable, net of current portion on the statements of financial position.

On June 11, 2025, the Company entered into a promissory note with an independent third party for $40,000 (the "June 11, 2025, Loan"). The June 11, 2025, Loan bears interest at a rate of 12% per annum, is unsecured and payable on demand.

On June 16, 2025, the Company entered into a promissory note with an independent third party for $125,000 (the "June 16, 2025, Loan"). The June 16, 2025, Loan bears interest at a rate of 12% per annum, is unsecured and payable on demand.

Between July 1, 2025, and August 21, 2025, the Company entered into promissory notes with unrelated third parties totaling $340,000 (the "July and August 2025 Notes"). The July and August 2025 Notes bear interest at a rate of 12% per annum, are unsecured and payable on demand. On August 22, 2025, the Company settled the principal balance of the June 11, 2025, Loan and the remaining $270,000 principal balance of the July and August 2025 Notes in cash.

Between July 1, 2025, and August 21, 2025, the Company entered into promissory notes with the Chief Operating Officer, a related party, totaling $17,350 (the "July and August 2025 Related Party Notes"). The July and August 2025 Related Party Notes bear interest at a rate of 12% per annum, are unsecured and payable on demand. On August 22, 2025, the Company settled the principal balance of the July and August 2025 Related Party Notes in cash. On August 21, 2025, the Company settled the principal balance of the June 16, 2025, Loan and $70,000 of the principal balance of the July and August 2025 Notes through the issuance of August 2025 Units.

As of September 30, 2025, the Company's shareholders' loans totaled $151,995 (December 31, 2024 - $151,995) and are included in loans payable, current portion on the unaudited condensed interim consolidated statements of financial position. During the nine months ended September 30, 2025, the Company made payments totaling $nil (2024 - $42,317) and drew a total of $nil (2024 - $nil) on the shareholders' loans.

(Expressed in Canadian Dollars)

10. CONVERTIBLE DEBENTURE

Activity related to the Company's convertible debenture is as follows:

Balance, December 31, 2022	$	366,208
Amortization of financing costs		29,725
Accretion and interests		46,202
Balance, December 31, 2023	$	442,135
Amortization of financing costs		7,431
Accretion and interests		11,649
Conversion to common shares		(461,215)
Balance, September 30, 2024	$	-
Balance, December 31, 2024	$	-
Balance, September 30, 2025	$	-

During the year ended December 31, 2022, the Company issued a $400,000 principal amount of unsecured convertible debentures (the "Debentures"). The Debentures were issued at original discount of 15% of the principal amount. The original discount amount is being amortized on straight line basis over the term of the Debentures. The Debentures bear interest at a rate of 8% per annum, calculated semi-annually and mature 24 months from the date of issuance. The principal of the Debentures, plus any interest accrual is convertible at the option of the Debentures' holders into one unit of the Company at the conversion price equal to $4.10 per unit. Each unit consists of one common share and one transferable share purchase warrant, with each warrant being exercisable into one common share at a price of $5.00 for a period of two years from the date of issuance. On inception, the Company allocated the total proceeds received of $340,551 between liabilities and equity. The equity component of $27,721 was valued using the residual method based on a discount rate of 12%.

During the three and nine months ended September 30, 2025, the Company has recorded accretion and interest expense in the amount of $nil, respectively (three and six months ended September 30, 2024 - $nil and $33,360, respectively).

On April 5, 2024, the Company entered into a debt settlement agreement with the holders of the Debentures in which the total principal and accrued interest obligations were cancelled in exchange for 1,143,403 of the Company's common shares and 571,700 warrants to purchase the Company's common shares at an exercise price of $0.60 per warrant exercised. The Company recognized a loss of convertible debt restructuring of $971,435 as a result of the conversion, which is the difference between the fair value of the common shares and warrants that would have been issued in connection with the original agreement and the fair value of the common shares and warrants that were issued in connection with the debt settlement agreement. Refer to Note 8 for further details of the impacts to share capital.

11. SHARE CAPITAL AND RESERVES

The Company has authorized an unlimited number of common shares and an unlimited number of preferred shares, both with no par value.

Rocket Doctor Acquisition

As discussed in Note 5, pursuant to the Rocket Doctor SPA, the Company issued 17,000,904 common shares of Rocket Doctor AI to satisfy the amounts owing under Rocket Doctor's existing SAFEs.

11. SHARE CAPITAL AND RESERVES (continued)

March 2025 Listed Issuer Financing Exemption

On March 13, 2025, the Company closed its previously announced brokered private placement under the Listed Issuer Financing Exemption (the "March 2025 Offering"). Pursuant to the March 2025 Offering, the Company issued 6,600,000 units (the "LIFE Units") at the issue price of $0.50 per LIFE Unit. Each LIFE Unit consists of one common share in the capital of the Company (a "Share") and one-half of one Share purchase warrant of the Company (each whole warrant being, a "Warrant"). Each Warrant entitles the holder thereof to purchase one Share at the exercise price of $0.75 until March 13, 2027.

The aggregate purchase price for the LIFE Units was $3,000,000 in cash, which was paid to the Company at closing, and was presented net of legal and other offering costs of $399,362. Pursuant to the Underwriting Agreement, the Company paid to the underwriter a cash commission of $264,000, reimbursed $83,252 of the underwriter's expenses, and issued 528,000 non-transferable broker warrants (the "March 2025 Broker Warrants"). Each March 2025 Broker Warrant is exercisable for one Unit at the price of $0.75 until March 13, 2027, with each Unit consisting of one common share and one-half of one common share purchase warrant. The March 2025 Broker Warrants and the underlying securities issued to the underwriter will be subject to a four month and one day hold period in accordance with Canadian securities laws.

The relative fair value of the net proceeds allocated to the common stock was estimated to be $1,871,075. The relative fair value of the net proceeds allocated to reserves was estimated to be $1,029,563 as determined based on the relative fair value allocation of the proceeds received. The Broker Warrants were valued using the Black-Scholes option pricing model using the following assumptions: (1) expected life of the warrants of 2 years, (2) expected volatility of 204%, (3) dividend yield of 0%, and (4) risk-free rate of 2.46%

October 2024 Capital Raise

On October 25, 2024, the Company closed a non-brokered private placement of 2,138,766 special warrants of the Company (each, an "October Special Warrant") at a price of $0.75 per October Special Warrant, for aggregate gross proceeds of $1,604,075 and 466,666 units of the Company (each, an "October Unit") at a price of $0.75 per October Unit, for aggregate gross proceeds of $350,000 (the "October Offering"). A total of $114,321 was allocated to the warrants included in the Units using the relative fair value method.

Each October Special Warrant automatically converts without payment of any additional consideration into one October Unit on the date that is the earlier of (i) the third business day after the date of filing a prospectus supplement (the "December Prospectus Supplement") to a short form base shelf prospectus qualifying the distribution of the shares and warrants issuable upon the conversion of the October Special Warrants, and (ii) 4 months and one day after the issue date of the October Special Warrants.

Each October Unit is comprised of one common share of the Company (each, a "Share") and one-half of one share purchase warrant (each whole, a "Warrant") of the Company, with each Warrant exercisable into one additional Share at an exercise price of $1.00 for two (2) years from the date of issuance.

On December 20, 2024, the Company filed the December Prospectus Supplement. As a result, the October Special Warrants automatically converted into 2,138,766 Shares and 1,069,383 Warrants. The assumptions used in the Black Scholes option pricing model to determine the grant date fair value of the Warrants included in the October Unit of $633,666 were: (1) expected life of 2.00 years, (2) expected volatility of 218%, (3) dividend yield of 0%, and (4) risk-free rate of 4.02%. A total of $523,940 was allocated to the warrants issued in the Units using the relative fair value method.

In connection with the October Offering, the Company has paid finders' fees of $117,383 and has issued an aggregate 156,378 non-transferable broker warrants (the "October Broker Warrants") to arm's-length parties. Each October Broker Warrant entitles the holder to purchase one Share (an "October Broker Share") at an exercise price of $1.00 per October Broker Share for a period of two (2) years from the date

11. SHARE CAPITAL AND RESERVES (continued)

of closing. The assumptions used in the Black Scholes option pricing model to determine the grant date fair value of the Broker Warrants of $99,538 were: (1) expected life of 2.00 years, (2) expected volatility of 271%, (3) dividend yield of 0%, and (4) risk-free rate of 4.11%.

Legal expenses and other transaction-related costs were $40,325. The Company intends to use the proceeds raised from the October Offering for working capital purposes.

March 2024 Capital Raise

On March 14, 2024, the Company closed a non-brokered private placement of 6,295,500 special warrants of the Company (each, a “March Special Warrant”) at a price of $0.40 per March Special Warrant, for aggregate gross proceeds of $2,518,200 and 975,000 units of the Company (each, a “March Unit”) at a price of $0.40 per March Unit, for aggregate gross proceeds of $390,000 (the “March Offering”). A total of $126,123 was allocated to the warrants included in the March Units using the relative fair value method.

Each March Special Warrant automatically converts without payment of any additional consideration into one March Unit on the date that is the earlier of (i) the third business day after a) a receipt from the applicable securities regulatory authorities for a (final) short form prospectus or b) the date of filing a prospectus supplement (the “June Prospectus Supplement”) to a short form base shelf prospectus qualifying the distribution of the March Units issuable upon the conversion of the March Special Warrants, and (ii) 4 months and one day after the issue date of the March Special Warrants.

Each March Unit is comprised of one Share and one-half of one Warrant of the Company, with each Warrant exercisable into one additional Share at an exercise price of $0.60 for two (2) years from the date of closing.

On June 18, 2024, the Company filed a Prospectus Supplement. As a result, the March Special Warrants automatically converted into 6,295,500 Shares and 3,147,750 Warrants. The assumptions used in the Black Scholes option pricing model to determine the grant date fair value of the Warrants included in the March Unit of $1,624,869 were: (1) expected life of 2.00 years, (2) expected volatility of 286%, (3) dividend yield of 0%, and (4) risk-free rate of 4.00%. A total of $814,268 was allocated to the Warrants issued in the March Units using the relative fair value method.

In connection with the March Offering, the Company has paid finder’s fees totaling $220,816 and issued an aggregate 552,040 non-transferable broker warrants (the “March Broker Warrants”) to arm’s-length parties. Each March Broker Warrant entitles the holder to purchase one Broker Share at an exercise price of $0.60 per Broker Share for a period of two (2) years from the date of closing. The assumptions used in the Black Scholes option pricing model to determine the grant date fair value of the March Broker Warrants of $284,963 were: (1) expected life of 2.00 years, (2) expected volatility of 286%, (3) dividend yield of 0%, and (4) risk-free rate of 4.00%. Legal expenses and other transaction-related costs were $64,973. The Company intends to use the proceeds raised from the March Offering for working capital purposes.

During the year ended December 31, 2023, the Company issued 18,005,716 common shares valued at $3,303,511 to settle accounts payable and loans payable, resulting in the Company recognizing a loss on settlement of debt of $1,500,009.

On September 29, 2023, the Company issued 10,000,000 common shares through a non-brokered private placement at $0.10 per share for gross proceeds of $1,000,000. The Company paid the finder’s fee of $17,500 and issued 175,000 finder’s warrants to arm’s length parties. Each finder’s warrant is exercisable into one common share at a price of $0.255 per share for a period of 2 years.

On October 5, 2023, the Company issued 2,475,000 common shares through a non-brokered private placement at $0.15 per share for gross proceeds of $371,250.

11. SHARE CAPITAL AND RESERVES (continued)

August 2025 Capital Raise

On August 21, 2025, the Company closed its non-brokered private placement of 3,677,400 special warrants of the Company (each, an “August 2025 Special Warrant”) at a price of $0.50 per Special Warrant, for aggregate gross proceeds of $1,838,700 and 4,792,000 units of the Company (each, an “August 2025 Unit”) at a price of $0.50 per August 2025 Unit, for aggregate gross proceeds of $2,396,000 (the “August 2025 Offering”). Each August 2025 Unit is comprised of one common share of the Company and one share purchase warrant of the Company, with each warrant exercisable into one share at an exercise price of $0.75 for 12 months from the date of issuance of the warrants.

Each August 2025 Special Warrant will automatically convert, for no additional consideration, into one Unit on the date (the “August 2025 Conversion Date”) that is the earlier of: (i) the third business day after the date of filing a prospectus supplement to a short form base shelf prospectus (the “2025 Prospectus Supplement”) qualifying the distribution of the common shares and warrants issuable upon the conversion of the August 2025 Special Warrants, and (ii) 4 months and one day after the issue date of the August 2025 Special Warrants. The Company filed a prospectus supplement on September 22, 2025, to its short form prospectus dated June 10, 2024, to qualify the distribution of securities underlying the 3,677,400 special warrants. The prospectus supplement qualified the special warrants to be converted into common shares and warrants on October 2, 2025.

In connection with the August 2025 Offering, the Company has paid finder’s fees totaling $201,616 and issued an aggregate of 403,232 non-transferable broker warrants (the “August 2025 Broker Warrants”) to independent third parties. Each August 2025 Broker Warrant entitles the holder to purchase one common share at an exercise price of $0.75 per share for a period of 12 months from the date of issuance of the August 2025 Broker Warrants.

Settlement of Convertible Debentures in Capital Shares

In connection with the debt settlement agreement described in Note 10, the Company issued 1,143,403 common shares with an issuance date fair value $1,169,468 and issued 571,700 warrants to purchase common shares of the Company at a price of $0.60 per share. The assumptions used in the Black Scholes option pricing model to determine the grant date fair value of the warrants of $263,182 were: (1) expected life of 2.00 years, (2) expected volatility of 285%, (3) dividend yield of 0%, and (4) risk-free rate of 3.76%.

Settlement of Debt in Common Shares

On July 5, 2024, the Company entered into Debt Settlement and Release Agreements with three third-party vendors to settle debt resulting from unpaid invoices totaling $650,000. On July 11, 2024, the Company issued a total of 1,160,713 common shares of the Company’s with a fair value of $1,149,406 to settle the debt.

Shares Issued for Services

On September 18, 2024, the Company issued 39,775 common shares, with a fair value of $30,627, in exchange for services. During the year ended December 31, 2023, the Company issued 5,717 common shares, with a fair value of $2,736 in exchange for services.

Stock Options

The Company adopted the 10% stock option plan (the “Option Plan”) on September 28, 2021, and re-approved by the Board on September 16, 2025. The Option Plan provides for the grant of stock options. Stock issued pursuant to awards granted under the 2021 Plan will consist of authorized but unissued common shares. Incentive stock options may be granted to directors, officers, employees and consultants of the Company or a subsidiary of the Company. The Company has reserved 10% of the Company’s issued and outstanding common shares. The exercise price shall not be less than the market value of the common shares.

(Expressed in Canadian Dollars)

11. SHARE CAPITAL AND RESERVES (continued)

The changes in options during the nine months ended September 30, 2025, and the year ended December 31, 2024, were as follows:

	Nine Months Ended September 30, 2025		Year Ended December 31, 2024	
	Number of Options	Weighted Average Exercise Price	Number of Options	Weighted Average Exercise Price
Opening	4,878,000	$0.52	2,051,500	$0.32
Granted	2,768,841	$0.48	3,168,000	$0.67
Expired	(150,000)	$0.55	(341,500)	$0.71
Ending	7,496,841	$0.46	4,878,000	$0.52
Exercisable	6,048,654	$0.50	3,237,750	$0.42

The weighted average assumptions that the Company used in the Black Scholes option pricing model to determine the grant date fair value of options granted during the six months ended June 30, 2024 were: (1) expected life of the options of 4.48 years, (2) expected volatility of 108%, (3) dividend yield of 0%, and (4) risk-free rate of 4.00%.

The weighted average assumptions that the Company used in the Black Scholes option pricing model to determine the grant date fair value of options granted during the six months ended June 30, 2025 were: (1) expected life of the options of 4.29 years, (2) expected volatility of 222%, (3) dividend yield of 0%, and (4) risk-free rate of 2.75%.

The weighted average assumptions that the Company used in the Black Scholes option pricing model to determine the grant date fair value of options granted during the nine months ended September 30, 2025 were: (1) expected life of the options of 39 years, (2) expected volatility of 239%, (3) dividend yield of 0%, and (4) risk-free rate of 2.83%.

On February 26, 2025, 100,000 stock options expired. During the twelve months ended December 31, 2024, 341,500 options were cancelled due to contract terminations. As a result, in accordance with IFRS 2, *Share-based Payment*, stock-based compensation expenses totaling $499,058 were reversed. During the nine months ended September 30, 2025, no options were cancelled.

(Expressed in Canadian Dollars)

11. SHARE CAPITAL AND RESERVES (continued)

As of September 30, 2025, outstanding incentive stock options were as follows:

Grant Date	Options Outstanding	Options Exercisable	Exercise Price	Expiry Date	Remaining Contractual Life (Years)
January 18, 2021	10,000	10,000	$ 0.32	12/1/2030	5.17
October 3, 2023	300,000	300,000	$ 0.20	10/3/2028	3.01
October 17, 2023	1,400,000	1,400,000	$ 0.25	10/17/2028	3.05
February 8, 2024	50,000	50,000	$ 0.55	3/1/2029	3.42
March 1, 2024	870,000	870,000	$ 0.55	3/1/2029	3.42
May 7, 2024	250,000	250,000	$ 0.60	5/7/2029	3.60
May 27, 2024	48,000	48,000	$ 0.51	5/27/2027	1.65
June 18, 2024	50,000	50,000	$ 0.55	6/18/2027	1.72
July 3, 2024	100,000	62,500	$ 0.89	7/3/2026	0.76
July 26, 2024	25,000	25,000	$ 0.85	7/26/2027	1.82
August 6, 2024	25,000	25,000	$ 0.73	8/6/2026	0.85
November 1, 2024	500,000	375,000	$ 0.75	11/1/2027	2.09
December 11, 2024	420,000	336,000	$ 0.75	12/11/2029	4.20
December 11, 2024	705,000	644,000	$ 0.75	12/11/2027	2.20
April 9, 2025	1,000,000	250,000	$ 0.50	4/9/2030	4.53
May 14, 2025	100,000	40,000	$ 0.50	5/14/2028	2.62
May 27, 2025	290,137	72,534	$ 0.50	5/27/2028	2.66
June 20, 2025	162,480	40,520	$ 0.50	6/20/2028	2.72
July 18, 2025	1,200,000	1,200,000	$ 0.45	07/18/2028	2.80
September 3, 2025	16,224	-	$ 0.50	09/03/2028	2.93
Total	7,496,841	6,048,654	$ 0.50		3.17

During the three and nine months ended September 30, 2025, the Company recorded stock-based compensation of $815,533 and $1,738,612 respectively related to share option vesting.

Special Warrants

During the nine months ended September 30, 2025, the Company issued 3,677,400 Special Warrants, however, the Company's prospectus supplement dated September 22, 2025, did not clear the Special Warrants until October 2, 2025.

	Nine Months Ended September 30, 2025	
	Number of March 2025 Broker Warrants	Weighted Average Exercise Price
Opening	-	-
Issued	3,677,400	$0.75
Converted	-	-
Ending	3,677,400	$0.75

The prospectus supplement qualified the distribution of 3,677,400 common shares and 3,677,400 common share purchase warrants. Each Warrant entitles the holder thereof to acquire one Common Share at an exercise price of $0.75 until 5:00 p.m. (Pacific Time) for a period of 12 months from the date of issuance.

(Expressed in Canadian Dollars)

11. SHARE CAPITAL AND RESERVES (continued)

Warrants

The changes in warrants during the nine months ended September 30, 2025, and the year ended December 31, 2024, were as follows:

	Nine Months Ended September 30, 2025		Year Ended December 31, 2024	
	Number of Warrants	Weighted Average Exercise Price	Number of Warrants	Weighted Average Exercise Price
Opening	5,439,393	$0.70	175,000	$0.26
Issued	9,123,232	$0.75	6,218,083	$0.70
Exercised	(338,866)	$0.60	(953,690)	$0.57
Ending	14,223,759	$0.73	5,439,393	$0.70

As of September 30, 2025, outstanding warrants are as follows:

Number of Warrants Outstanding	Weighted average exercise price		Expiry Date	Weighted average life remaining (years)
3,292,600	$	0.60	March 13, 2026	0.4
548,834	$	0.60	April 5, 2026	0.5
389,710	$	1.00	October 25, 2026	1.1
1,069,383	$	1.00	December 27, 2026	1.2
3,300,000	$	0.75	March 13, 2027	1.4
428,000	$	0.75	March 13, 2027	1.4
5,195,232	$	0.75	August 21, 2026	0.9
14,223,759	**$**	**0.73**		**0.7**

Restricted Share Units

In September 2021, the Company adopted the Restricted Share Unit (“RSU”) Plan (“RSU Plan”). The maximum number of common shares made available for issuance pursuant to the RSU Plan is determined by the Board of Directors of the Company (the “Board”) but shall not exceed 10% of the common shares issued and outstanding from time to time. The Board is authorized to provide for the awarding, granting, vesting, settlement, expiration, and method of settlement of RSUs. As of September 30, 2025, and December 31, 2024, 6,411,384 and 2,735,000, respectively, RSUs were outstanding under the RSU Plan, and no shares of Common Stock were reserved for future grants under the RSU Plan.

The details of the RSUs” issued are as follows:

	Nine Months Ended September 30, 2025	Year Ended December 31, 2024
	Number of RSUs	Number of RSUs
RSUs outstanding, beginning	2,735,000	1,250,000
Granted	4,346,384	2,435,000
Exercised	(670,000)	(950,000)
Expired	-	-
RSU outstanding, ending	**6,411,384**	**2,735,000**
RSUs vested	**2,617,872**	**1,600,000**

(Expressed in Canadian Dollars)

11. SHARE CAPITAL AND RESERVES (continued)

As of September 30, 2025, outstanding RSUs are as follows:

RSUs Outstanding	Weighted Average Share Price on Grant Date for Outstanding RSUs		RSUs Vested	Weighted Average Share Price on Grant Date for Vested RSUs		Expiry Date	Weighted Average Life Remaining (years)
1,000,000	$	0.23	1,000,000	$	0.23	October 17, 2026	1.0
110,000	$	0.46	110,000	,$	0.46	February 8, 2027	1.4
100,000	$	0.70	100,000	$	0.70	April 16, 2027	1.5
201,000	$	0.63	164,000	$	0.63	December 11, 2027	2.2
150,000	$	0.23	50,000	$	0.23	October 17, 2028	3.0
504,000	$	0.63	416,000	$	0.63	December 11, 2029	4.2
1,600,000	$	0.44	-	$	-	April 9, 2027	1.5
100,000	$	0.45	40,000	$	0.45	May 14, 2028	2.6
1,781,568	$	0.44	455,392	$	-	May 27, 2028	2.7
99,920	$	0.47	12,480	$	-	June 20, 2028	2.7
700,000	$	0.47	280,000	$	0.47	June 20, 2030	4.7
64,896	$	0.69	-	$	0.47	June 20, 2030	2.9
6,411,384	**$**	**0.43**	**2,617,872**	**$**	**0.41**		**2.4**

During the three and nine months ended September 30, 2025, the Company recorded stock-based compensation of $402,056 and $1,207,377, respectively related to RSU vesting.

12. MANAGEMENT OF CAPITAL

The Company considers its capital structure to include the components of loans payable and shareholders' equity. Management's objective is to ensure that there is sufficient capital to minimize liquidity risk and to continue as a going concern. Although the Company has been successful in the past in obtaining financing, there can be no assurance that the Company will be able to obtain adequate financing in the future, or that the terms of such financings will be favourable. The Company is not subject to any externally imposed capital requirements. There were no changes in the Company's approach to managing capital during the nine months ended September 30, 2025.

13. FINANCIAL INSTRUMENTS

Classification of financial instruments

Financial instruments included in the unaudited condensed interim consolidated statement of financial position are as follows:

As of			September 30, 2025		December 31, 2024
Cash	Amortized cost	$	1,889,135	$	1,231,999
Accounts receivable	Amortized cost	$	77,068	$	-
Notes receivable	Amortized Cost	$	338,388	$	-
Trade payables	Amortized cost	$	1,351,608	$	334,430
Contingent consideration	Fair value through profit and loss	$	8,578,463	$	-
Loan payable	Amortized cost	$	436,230	$	151,995

13. FINANCIAL INSTRUMENTS (continued)

Fair value

The fair value hierarchy has three levels to classify the inputs to valuation techniques used to measure fair value described as follows:

Level 1 – Unadjusted quoted prices in active markets for identical assets or liabilities;

Level 2 – Inputs other than quoted prices that are observable for the assets or liabilities either directly or indirectly; and

Level 3 – Inputs that are not based on observable market data.

The Company's financial instruments consisted of cash, note receivable, accounts payable and accrued liabilities, contingent consideration and loan payable. The carrying values of cash, note receivable, accounts payable and accrued liabilities, and loan payable approximate fair value due to the short-term nature of the instruments. Contingent consideration is classified as a financial liability at fair value through profit or loss. The contingent consideration was discounted using the Company's effective borrowing rate upon initial recognition. This rate has not materially changed at the reporting date.

Risk management

The Board of Directors has overall responsibility for the establishment and oversight of the Company's risk management framework. The Company's risk management policies are established to identify and analyze the risks faced by the Company to set appropriate risk limits and controls and to monitor risks and adherence to limits. Risk management policies and systems are reviewed regularly to reflect changes in market conditions and the Company's activities. The Company has exposure to the following risks from its use of financial instruments:

Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. As of September 30, 2025, the Company's working capital was a deficit of $4,713,486, which was mainly due to liabilities assumed in the acquisition of Rocket Doctor. As a result, the Company is subject to liquidity risk. Historically, the Company's primary source of funding has been the issuance of equity securities for cash, primarily through private placements and loans from related and other parties. The Company's access to financing is always uncertain. There can be no assurance of continued access to significant equity funding.

Interest rate risk

Interest rate risk refers to the risk that the fair value of financial instruments or future cash flows associated with the instruments will fluctuate due to changes in market interest rates. The Company is exposed to interest rate risk on its notes payable and long-term debt. The terms and conditions of the obligations are disclosed in Note 9.

Credit risk

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations.

The potential concentration of credit risk consists mainly of cash, accounts receivable and note receivable. The Company limits its counterparty exposures from its cash by only dealing with well-established financial institutions of a high-quality credit standing. The maximum exposure to credit risk is represented by the carrying amount of each financial asset on the statement of financial position.

(Expressed in Canadian Dollars)

13. FINANCIAL INSTRUMENTS (continued)

At the reporting date the majority of the Company's cash resources were deposited with reputable established financial institutions. As a result, management believes the Company is not exposed to significant credit risk due to the credit worthiness of these counterparties.

Foreign currency risk

Foreign currency risk arises from holdings of financial assets and liabilities in currencies other than the functional currency to which they relate. The Company and its subsidiaries have minimal such holdings, consequently foreign currency risk is considered low.

14. SEGMENTED INFORMATION

The Company operates primarily in two business segments, as discussed below. The Company has its head office in Canada and operates in the U.S.A and Canada.

Operating segments are defined as the components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision makers in deciding how to allocate resources and in assessing performance. The Company's chief operating decision makers direct the allocation of resources to operating segments based on the profitability, cash flows, and growth opportunities of each respective segment.

Prior to the close of the acquisition of Rocket Doctor, pursuant to the Rocket Doctor SPA, on April 9, 2025, the Company operated primarily in one business segment, which is the supply of personalized health care information.

The Company classifies its business interests into reportable segments which are:

Rocket Doctor AI: supply personalized health care information

Rocket Doctor: provide a digital health platform to assist physicians to provide health care to patients

Segmented information for the nine months ended September 30, 2025, and 2024 is as follows:

Nine Months Ended September 30, 2025	**Rocket Doctor AI**	**Rocket Doctor**	**Total**
Revenue	$ 25,369	$ 1,016,510	$ 1,041,879
Direct Costs	$ -	$ 119,023	$ 119,023
Gross Profit	$ 25,369	$ 897,487	$ 922,856
Segment Profit (Loss)	$ (6,493,603)	$ (1,862,264)	$ (8,355,867)
Segment Assets	$ 1,884,084	$ 18,502,192	$ 20,386,276

Nine Months Ended September 30, 2024	**Rocket Doctor AI**	**Total**
Revenue	$ 10,990	$ -
Direct Costs	$ -	$ -
Gross Profit	$ -	$ -
Segment Profit (Loss)	$ (5,303,432)	$ (5,303,432)
Segment Assets	$ 883,276	$ 883,276

During the nine months ended September 30, 2025, the Company generated revenues of $92,525 in the U.S.A. and $949,354 in Canada.

(Expressed in Canadian Dollars)

15. RELATED PARTY TRANSACTIONS

Transactions with key management personnel

Key management personnel include those persons having authority and responsibility for planning, directing, and controlling the activities of the Company as a whole. The Company has determined that key management personnel consist of executive and non-executive members of the Board of Directors and corporate officers. The aggregate values of transactions relating to key management are as follows:

Nine Months Ended September 30,		2025		2024
Salaries, Wages, Research and Consulting fees				
Chief Executive Officer	$	180,000	$	180,000
Chief Financial Officer	$	387,157	$	153,772
Former Chief Financial Officer & Director	$	-	$	14,700
Chief Operating Officer	$	90,000	$	50,000
Corporate Secretary	$	53,436	$	37,074
Chief Medical Officer & Director	$	62,929	$	126,468

Balances due to related parties

Amounts due to related parties are unsecured, non-interest bearing and have no fixed terms of repayment.

The Company has the following amounts due to related parties:

		As of			
Due to Related parties	**Nature**		**September 30, 2025**		**December 31, 2024**
Chief Executive Officer	Deferred wages	$	-	$	-
Chief Financial Officer	Consulting fees	$	-	$	19,431
Chief Operating Officer	Deferred wages	$	-	$	-
Chief Medical Officer & Director	Loan	$	70,490	$	76,995
Chief Medical Officer & Director	Deferred wages	$	-	$	-

16. CONTINGENCIES

From time to time, the Company may be involved in claims and litigations as part of its normal course of business. Accruals are made in instances where it is probable that liabilities have been incurred and where such liabilities can be reasonably estimated. Although it is possible that liabilities may be incurred in instances for which no accruals have been made, based on the information currently available, the Company does not believe that any additional provisions are required to be recognized.

17. SUBSEQUENT EVENTS

On September 22, 2025, the Company filed a prospectus supplement dated September 22, 2025, to its short form base shelf prospectus dated June 10, 2024, to qualify the distribution of securities underlying 3,677,400 special warrants issued by the Company on August 21, 2025. The Prospectus Supplement qualifies the distribution of 3,677,400 common shares and 3,677,400 common share purchase. Each warrant entitles the holder thereof to acquire one Common Share at an exercise price of $0.75 for a period of 12 months from the date of issuance. The Special Warrants were deemed to be converted into Common Shares and Warrants on October 2, 2025.

17. SUBSEQUENT EVENTS (continued)

On October 2, 2025, the Company entered into a reseller agreement with Remmie, Inc., the Seattle-based medical device company behind the Remmie 4, an FDA and Health Canada MDEL cleared USB-smart otoscope designed for easy, at-home ear exams.

On October 9, 2025, the Company announced it is receiving advisory services and funding of up to $75,000 from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to develop secure communications functionality, and funding of up to $25,000 from the CanExport SMEs program to accelerate product innovation and U.S. market growth.

On October 15, 2025, the Company announced in collaboration with Rush River Research has been awarded a highly competitive NIH Small Business Innovation Research (SBIR) grant from the National Institute on Minority Health and Health Disparities (National Institutes of Health). This Phase 2 award advances the collection of culturally sensitive family medical histories using the application of Artificial Intelligence (AI). The US $2 Million two-year award supports the further development and commercialization of important research advances that were developed in Phase 1. With experts drawn from across the United States and with the additional contribution of engineering and design excellence from Rush River Research, the award will provide the Company with over US $500,000 to further develop and integrate innovative approaches that enhance Treatment's handling of medical history data across several commercial platforms.

On November 7, 2025, the Company announced that it has granted an aggregate 831,356 restricted share units ("**RSUs**") and 20,964 stock options to consultants and employees of the Company and its subsidiary, Rocket Doctor Inc. The Options are each exercisable for one common share of the Company at an exercise price of C$0.82 per share for a period of three years from the grant date and subject to vesting provisions. 325,000 RSUs are valid for a term of two years and 506,356 RSUs are valid for a term of three years. 203,000 RSUs vest immediately and 628,356 are subject to vesting provisions. All Options and RSUs are subject to the terms of the Company's equity plans and applicable securities law hold periods.

On November 19, 2025, the Company announced it has entered into a definitive share purchase agreement dated November 19, 2025, amongst the Company, Alea Health Holdings Ltd. and the ordinary shareholders of to acquire 100% of the issued and outstanding securities of Alea. Pursuant to the terms of the Definitive Agreement, the Company will acquire 100% of the issued and outstanding ordinary shares in the capital of Alea by making the following payments: (i) a cash payment of US $15,000, which has been paid as of the date hereof; (ii) the issuance of 285,712 common shares in the capital of the Company on the closing date *pro rata* to the Alea Shareholders, with a deemed value of CAD $0.70 per Consideration Share, subject to the minimum pricing requirements of the Canadian Securities Exchange. The Company has also agreed to assume and satisfy Alea's obligations under a Simple Agreement for Future Equity by paying the US $180,000 principal balance of the SAFE Note in equal monthly installments of US $22,500 per month until paid in full. The Proposed Transaction remains subject to certain closing conditions, including, without limitation: (a) the entering into of employment or consulting agreements with certain key Alea employees; and (b) the receipt of all required regulatory and third-party approvals, including the CSE, and if applicable, the approval of the Alea Shareholders. There can be no guarantees that the Proposed Transaction will be completed as contemplated or at all.